基本信息
views: 9
Career Trajectory
Bio
His overarching mission is to translate research from ‘bench to bedside’; to improve understanding of mechanisms that modulate risk vs resilience, and so develop new diagnostic approaches, treatments, and services.
In autism Professor Murphy established the MRC UK AIMS multi centre imaging network – the first in Europe. From this he developed two European Union funded Innovative Medicines Initiatives in autism. The first was called EU-AIMS . The successor to this (EU AIMS-2-TRIALS) (https://www.aims-2-trials.eu/) brings together 48 partners (including academics, charities, autistic individuals and families, regulators and industry) across 14 European countries. The research programme includes a range of studies. These will explore how autism develops, from before birth to adulthood, and how this varies in different people. We will look for biological markers which indicate whether a person has, or may develop, particular characteristics. These markers may help to identify who could ultimately benefit from particular treatments. We will also test treatments. EU AIMS-2-TRIALS links to other groups in North America, South Africa, China, Australia, and Pakistan .
Research Interests
His main interest is in normal brain development, and how abnormalities in this process lead to neurodevelopmental/neuropsychiatric disorders. He supervises PhD Students in
Fetal/neonatal/infant brain development
Brain changes across the lifespan
Risk vs protective mechanisms underpinning the emergence of a variety of neurodevelopmental disorders including autism, ADHD, epilepsy and psychosis. And factors modulating outcome and response to treatment
Disorders of social behaviour in children and adults – e.g. conduct disorder, callous unemotional behaviour, and psychopathy
The impact of specific genetic abnormalities on brain and behaviour
Biomarker discovery and validation.
Treatment trials (including non pharmacological approaches).
Pharmacochallenge studies using brain imaging
In autism Professor Murphy established the MRC UK AIMS multi centre imaging network – the first in Europe. From this he developed two European Union funded Innovative Medicines Initiatives in autism. The first was called EU-AIMS . The successor to this (EU AIMS-2-TRIALS) (https://www.aims-2-trials.eu/) brings together 48 partners (including academics, charities, autistic individuals and families, regulators and industry) across 14 European countries. The research programme includes a range of studies. These will explore how autism develops, from before birth to adulthood, and how this varies in different people. We will look for biological markers which indicate whether a person has, or may develop, particular characteristics. These markers may help to identify who could ultimately benefit from particular treatments. We will also test treatments. EU AIMS-2-TRIALS links to other groups in North America, South Africa, China, Australia, and Pakistan .
Research Interests
His main interest is in normal brain development, and how abnormalities in this process lead to neurodevelopmental/neuropsychiatric disorders. He supervises PhD Students in
Fetal/neonatal/infant brain development
Brain changes across the lifespan
Risk vs protective mechanisms underpinning the emergence of a variety of neurodevelopmental disorders including autism, ADHD, epilepsy and psychosis. And factors modulating outcome and response to treatment
Disorders of social behaviour in children and adults – e.g. conduct disorder, callous unemotional behaviour, and psychopathy
The impact of specific genetic abnormalities on brain and behaviour
Biomarker discovery and validation.
Treatment trials (including non pharmacological approaches).
Pharmacochallenge studies using brain imaging
Research Interests
Papers共 1139 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Louise Emmett,Nathan Papa, Thomas A Hope,Wolfgang Fendler, Jeremie Calais,Irene Burger, Matthias Eiber,Francesco Barbato, Daniel Moon,William Counter, Nikeith John, Alan Xue,
The Journal of urologyno. 2 (2024): 299-309
Translational andrology and urologyno. 4 (2024): 653-656
Jodie Ai Ling McDonald,Jonathan O'Brien,Brian Kelly,Declan Murphy,Nathan Lawrentschuk,Renu Eapen,Catherine Mitchell
Journal of clinical pathology (2024)
European Urologyno. 2 (2024): e60-e61
Teresa Del Bianco,Meng-Chuan Lai,Luke Mason,Mark H Johnson, Tony Charman,Eva Loth,Tobias Banaschewski,Jan Buitelaar,Declan G M Murphy,Emily J H Jones, AIMS--TRIALS LEAP Team
Scientific reportsno. 1 (2024): 14038-14038
Madeleine Bloomfield,Alexandra Lautarescu,Síofra Heraty, Sarah Douglas,Pierre Violland, Roderik Plas, Anjuli Ghosh, Katrien Van den Bosch, Eliza Eaton,Michael Absoud,Roberta Battini, Ana Blázquez Hinojosa,
BMJ openno. 6 (2024): e080746-e080746
European Urology (2024)
CANCERSno. 5 (2024): 939
European Urology (2024)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn